Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 51 Published: August 30, 2022 Report Code: GDGMDHC22281IDB

  • Overview
  • Key Players
  • Contents
  • Tables
  • Figures
  • FAQ
  • Listen
    https://www.ispeech.org

Thrombotic Thrombocytopenic Purpura (TTP) is a rare blood disorder characterized by clotting in small blood vessels of the body (thromboses), resulting in a low platelet count. Symptoms include bleeding into the skin or mucus membranes, confusion, fever, headache, heart rate, shortness of breath, speech changes, weakness, and yellowish color to the skin (jaundice).

The TTP pipeline drugs market research report outlays comprehensive information on the TTP targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type, that are being developed by companies/universities. It also reviews key players involved in TTP targeted therapeutics development with respective active and dormant or discontinued projects.

TTP Pipeline Drugs Market Segmentation by Targets

Some of the primary targets in the Thrombotic Thrombocytopenic Purpura pipeline drugs market are A Disintegrin and Metalloproteinase With Thrombospondin Motifs 13, Von Willebrand Factor, and Plasminogen.

TTP Pipeline Drugs Market Analysis, by Targets

TTP Pipeline Drugs Market Analysis, by Targets

To know more about the targets in the TTP pipeline drugs market, download a free report sample

TTP Pipeline Drugs Market Segmentation by Mechanisms of Action

The primary mechanisms of action in the Thrombotic Thrombocytopenic Purpura pipeline drugs market are Von Willebrand Factor Inhibitor, A Disintegrin And Metalloproteinase With Thrombospondin Motifs 13 Activator, A Disintegrin And Metalloproteinase With Thrombospondin Motifs 13 Replacement, and Plasminogen Activator.

TTP Pipeline Drugs Market Analysis, by Mechanisms of Action

TTP Pipeline Drugs Market Analysis, by Mechanisms of Action

To know more about the MoA in the TTP pipeline drugs market, download a free report sample

TTP Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Thrombotic Thrombocytopenic Purpura pipeline drugs market are Intravenous and Subcutaneous.

TTP Pipeline Drugs Market Analysis, by Routes of Administration

TTP Pipeline Drugs Market Analysis, by Routes of Administration

To know more about the RoA in the TTP pipeline drugs market, download a free report sample

TTP Pipeline Drugs Market Segmentation by Molecule Type

The key molecule types in the TTP pipeline drugs market are Recombinant Enzyme, Aptamer, Fusion Protein, Gene Therapy, Gene-Modified Cell Therapy, Monoclonal Antibody, and Recombinant Protein.

TTP Pipeline Drugs Market Analysis, by Molecule Type

TTP Pipeline Drugs Market Analysis, by Molecule Type

To know more about the molecule type in the TTP pipeline drugs market, download a free report sample

Competitive Landscape

Some of the leading companies in the TTP pipeline drugs market are GC Biopharma Corp, KM Biologics Co Ltd, PlateletBio, Sanofi, TagCyx Biotechnologies, Takeda Pharmaceutical Co Ltd, and TargED Biopharmaceuticals BV.

TTP Pipeline Drugs Market Analysis, by Leading Companies

TTP Pipeline Drugs Market Analysis, by Leading Companies

To know more about the leading companies in the TTP pipeline drugs market, download a free report sample

TTP Pipeline Drugs Market Report Overview

Key Targets A Disintegrin and Metalloproteinase With Thrombospondin Motifs 13, Von Willebrand Factor, and Plasminogen
Key Mechanisms of Action Von Willebrand Factor Inhibitor, A Disintegrin And Metalloproteinase With Thrombospondin Motifs 13 Activator, A Disintegrin And Metalloproteinase With Thrombospondin Motifs 13 Replacement, and Plasminogen Activator
Key Routes of Administration Intravenous and Subcutaneous
Key Molecule Types Recombinant Enzyme, Aptamer, Fusion Protein, Gene Therapy, Gene-Modified Cell Therapy, Monoclonal Antibody, and Recombinant Protein
Key Companies GC Biopharma Corp, KM Biologics Co Ltd, PlateletBio, Sanofi, TagCyx Biotechnologies, Takeda Pharmaceutical Co Ltd, and TargED Biopharmaceuticals BV

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Players

GC Biopharma Corp

KM Biologics Co Ltd

PlateletBio

Sanofi

TagCyx Biotechnologies

Takeda Pharmaceutical Co Ltd

TargED Biopharmaceuticals BV

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Overview

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Companies Involved in Therapeutics Development

GC Biopharma Corp

KM Biologics Co Ltd

PlateletBio

Sanofi

TagCyx Biotechnologies

Takeda Pharmaceutical Co Ltd

TargED Biopharmaceuticals BV

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Drug Profiles

caplacizumab – Drug Profile

Product Description

Mechanism Of Action

History of Events

cinaxadamtase alfa – Drug Profile

Product Description

Mechanism Of Action

History of Events

GC-1126A – Drug Profile

Product Description

Mechanism Of Action

Gene Therapy for Thrombotic Thrombocytopenic Purpura – Drug Profile

Product Description

Mechanism Of Action

Gene Therapy to Activate ADAMTS13 for Thrombotic Thrombocytopenic Purpura – Drug Profile

Product Description

Mechanism Of Action

History of Events

Microlyse – Drug Profile

Product Description

Mechanism Of Action

Recombinant ADAMTS-13 Replacement for Thrombotic Thrombocytopenic Purpura – Drug Profile

Product Description

Mechanism Of Action

TAGX-0004 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Dormant Projects

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Discontinued Products

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Product Development Milestones

Featured News & Press Releases

Feb 14, 2022: Sanofi files NDA for rare blood disease drug in Japan

Jul 02, 2021: Sanofi to present on Cablivi at ISTH 2021

Nov 12, 2020: NICE recommends innovative treatment for severe blood disorder for NHS use

Apr 30, 2020: CHMP adopts positive opinion for treatment of acquired thrombotic thrombocytopenic purpura with caplacizumab

Mar 02, 2020: Cablivi (caplacizumab) approved by Health Canada for adults living with acquired thrombotic thrombocytopenic purpura (aTTP)

Dec 17, 2019: Sanofi wins prestigious drug discovery award for innovative Rare Blood Clotting Disorder treatment

Nov 06, 2019: New data on Cablivi to be presented at ASH 2019 highlight Sanofi’s commitment to treat challenging blood cancers and rare blood disorders

Mar 21, 2019: Biologics by McKesson expands specialty pharmacy capabilities to serve patients with rare and complex conditions

Feb 07, 2019: FDA approves Sanofi’s Cablivi as first therapy for rare blood disorder

Jan 09, 2019: New England Journal of Medicine publishes positive results of the pivotal trial of Cablivi (caplacizumab) for rare blood clotting disorder

Oct 30, 2018: Pharm-Olam conducts pivotal orphan disease trial, leads to first therapeutic approved for the treatment for acquired thrombotic thrombocytopenic purpura

Sep 21, 2018: A Trojan Horse delivery of possible treatment for a rare, potentially deadly, blood-clotting disorder

Sep 03, 2018: Sanofi’s Cablivi receives EC approval to treat rare blood disorder

Jun 29, 2018: Sanofi: CHMP recommends approval of Cablivi (caplacizumab)

Dec 21, 2017: Ablynx Announces Positive Data From Its Japanese Ethno-Bridging Study Of Caplacizumab

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Pipeline by GC Biopharma Corp, 2022

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Pipeline by KM Biologics Co Ltd, 2022

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Pipeline by PlateletBio, 2022

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Pipeline by Sanofi, 2022

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Pipeline by TagCyx Biotechnologies, 2022

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Pipeline by Takeda Pharmaceutical Co Ltd, 2022

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Pipeline by TargED Biopharmaceuticals BV, 2022

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Dormant Projects, 2022

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development for Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease), 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently Asked Questions

Some of the targets in the TTP pipeline drugs market are  A Disintegrin and Metalloproteinase With Thrombospondin Motifs 13, Von Willebrand Factor, and Plasminogen.

The primary mechanism of action in the TTP pipeline drugs market are Von Willebrand Factor Inhibitor, A Disintegrin And Metalloproteinase With Thrombospondin Motifs 13 Activator, A Disintegrin And Metalloproteinase With Thrombospondin Motifs 13 Replacement, and Plasminogen Activator.

The routes of administration in the TTP pipeline drugs market are Intravenous and Subcutaneous.

The molecule types in the TTP pipeline drugs market are Recombinant Enzyme, Aptamer, Fusion Protein, Gene Therapy, Gene-Modified Cell Therapy, Monoclonal Antibody, and Recombinant Protein.

Some of the leading companies in the TTP pipeline drugs market are GC Biopharma Corp, KM Biologics Co Ltd, PlateletBio, Sanofi, TagCyx Biotechnologies, Takeda Pharmaceutical Co Ltd, and TargED Biopharmaceuticals BV.

$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.